Idera Pharmaceuticals Inc. (NASDAQ:IDRA) Director Maxine Gowen acquired 4,102 shares of Idera Pharmaceuticals stock in a transaction dated Monday, October 3rd. The stock was purchased at an average cost of $2.56 per share, for a total transaction of $10,501.12. Following the completion of the purchase, the director now owns 10,543 shares in the company, valued at approximately $26,990.08. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) opened at 2.61 on Thursday. The firm’s market cap is $316.80 million. Idera Pharmaceuticals Inc. has a 52-week low of $1.19 and a 52-week high of $4.42. The company’s 50 day moving average is $2.19 and its 200-day moving average is $1.81.
Idera Pharmaceuticals (NASDAQ:IDRA) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Idera Pharmaceuticals had a negative net margin of 6,169.32% and a negative return on equity of 64.09%. On average, equities analysts predict that Idera Pharmaceuticals Inc. will post ($0.45) EPS for the current fiscal year.
A number of research firms have recently commented on IDRA. Zacks Investment Research lowered shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Idera Pharmaceuticals in a research note on Tuesday, August 2nd.
A number of large investors have recently made changes to their positions in IDRA. JPMorgan Chase & Co. increased its stake in shares of Idera Pharmaceuticals by 5.9% in the first quarter. JPMorgan Chase & Co. now owns 3,349,700 shares of the company’s stock worth $6,632,000 after buying an additional 187,625 shares in the last quarter. State Street Corp increased its stake in shares of Idera Pharmaceuticals by 10.7% in the second quarter. State Street Corp now owns 1,332,201 shares of the company’s stock worth $2,041,000 after buying an additional 129,033 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Idera Pharmaceuticals by 4.3% in the second quarter. BlackRock Fund Advisors now owns 2,332,615 shares of the company’s stock worth $3,569,000 after buying an additional 97,125 shares in the last quarter. BlackRock Investment Management LLC increased its stake in shares of Idera Pharmaceuticals by 7.3% in the second quarter. BlackRock Investment Management LLC now owns 334,389 shares of the company’s stock worth $512,000 after buying an additional 22,791 shares in the last quarter. Finally, Creative Planning increased its stake in shares of Idera Pharmaceuticals by 11.8% in the second quarter. Creative Planning now owns 121,300 shares of the company’s stock worth $186,000 after buying an additional 12,800 shares in the last quarter. 28.44% of the stock is currently owned by institutional investors and hedge funds.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.